Latest Breaking News On - Usual treatment - Page 1 : comparemela.com

Data presented today show a reduction in treated spontaneous and traumatic bleeds and mean annualised bleeding rate (ABR) of 1.7 with concizumab[1]London, UK, 10 July 2022 – Novo Nordisk announced the phase 3 results of the explorer7 study, assessing the efficacy and safety of prophylactic treatment with conci.

United kingdomCity ofMartin langeNovo nordiskVictor jimYork stock exchangeCenters for diseaseInternational society of thrombosisSafety of prophylactic administration concizumabDevelopment at novo nordiskHaematology departmentHaemostasis annual congressPaz university hospitalA approach using national registriesInternational societyNasdaq copenhagen